Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182. doi:10.1126/science.3798106
   PubMed Web of Science ®Google Scholar
• Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14(4):320–368. doi:10.1634/theoncologist.2008-0230
   PubMed Web of Science ®Google Scholar
• Zell JA, Tsang WY, Taylor TH, Mehta RS, Anton-Culver H. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California cancer registry. Breast Cancer Res. 2009;11(1):R9. doi:10.1186/bcr2225
   PubMed Web of Science ®Google Scholar
• Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12(Suppl 1):S3–S8. doi:10.1093/annonc/12.suppl_1.s3
   PubMed Web of Science ®Google Scholar
• Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389(10087):2415–2429. doi:10.1016/S0140-6736(16)32417-5
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–137. doi:10.1038/35052073
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341–354. doi:10.1038/nrc1609
   PubMed Web of Science ®Google Scholar
• Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res. 2000;77:25–79.
   PubMed Web of Science ®Google Scholar
• Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. Embo J. 1996;15(10):2452–2467. doi:10.1200/JCO.2013.53.9288
   PubMed Web of Science ®Google Scholar
• Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 1996;16(10):5276–5287. doi:10.1128/mcb.16.10.5276
   PubMed Web of Science ®Google Scholar
• Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res. 2003;284(1):54–65. doi:10.1016/s0014-4827(02)00101-5
   PubMed Web of Science ®Google Scholar
• Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14(3):737–744. doi:10.1200/JCO.1996.14.3.737
   PubMed Web of Science ®Google Scholar
• Ghosh R, Narasanna A, Wang SE, et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011;71(5):1871–1882. doi:10.1158/0008-5472.CAN-10-1872
   PubMed Web of Science ®Google Scholar
• Junttila TT, Akita RW, Parsons K, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009;15(5):429–440. doi:10.1016/j.ccr.2009.03.020
   PubMed Web of Science ®Google Scholar
• Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001;61(12):4744–4749.
   PubMed Web of Science ®Google Scholar
• Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett. 2006;232(2):123–138. doi:10.1016/j.canlet.2005.01.041
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51. doi:10.1056/NEJMra043186
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–1283. doi:10.1056/NEJMoa0910383
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32. doi:10.1016/S1470-2045(11)70336-9
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792. doi:10.1056/NEJM200103153441101
   PubMed Web of Science ®Google Scholar
• Kumler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev. 2014;40(2):259–270. doi:10.1016/j.ctrv.2013.09.002
   PubMed Web of Science ®Google Scholar
• Garrett JT, Arteaga CL. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther. 2011;11(9):793–800. doi:10.4161/cbt.11.9.15045
   PubMed Web of Science ®Google Scholar
• Jin MH, Nam AR, Park JE, Bang JH, Bang YJ, Oh DY. Resistance mechanism against trastuzumab in HER2-positive cancer cells and its negation by Src inhibition. Mol Cancer Ther. 2017;16(6):1145–1154. doi:10.1158/1535-7163.MCT-16-0669
   PubMed Web of Science ®Google Scholar
• Luque-Cabal M, Garcia-Teijido P, Fernandez-Perez Y, Sanchez-Lorenzo L, Palacio-Vazquez I. Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it. Clin Med Insights Oncol. 2016;10(Suppl 1):21–30. doi:10.4137/CMO.S34537
   PubMedGoogle Scholar
• Li Y, Chu J, Feng W, et al. EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties. Faseb J. 2019;33(4):4851–4865. doi:10.1096/fj.201701561RRRR
   PubMed Web of Science ®Google Scholar
• Richard S, Selle F, Lotz JP, Khalil A, Gligorov J, Soares DG. Pertuzumab and trastuzumab: the rationale way to synergy. An Acad Bras Cienc. 2016;88(Suppl 1):565–577. doi:10.1590/0001-3765201620150178
   PubMed Web of Science ®Google Scholar
• Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2(2):127–137.
   PubMed Web of Science ®Google Scholar
• Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64(7):2343–2346.
   PubMed Web of Science ®Google Scholar
• Metzger-Filho O, Winer EP, Krop I. Pertuzumab: Optimizing HER2 blockade. Clin Cancer Res. 2013;19(20):5552–5556. doi:10.1158/1078-0432.CCR-13-0518
   PubMed Web of Science ®Google Scholar
• Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005;65(23):11118–11128. doi:10.1158/0008-5472.CAN-04-3841
   PubMed Web of Science ®Google Scholar
• Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68(14):5878–5887. doi:10.1158/0008-5472.CAN-08-0380
   PubMed Web of Science ®Google Scholar
• Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445(7126):437–441. doi:10.1038/nature05474
   PubMed Web of Science ®Google Scholar
• Amin DN, Sergina N, Ahuja D, et al. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med. 2010;2(16):16ra7. doi:10.1126/scitranslmed.3000389
   PubMed Web of Science ®Google Scholar
• Garrett JT, Olivares MG, Rinehart C, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A. 2011;108(12):5021–5026. doi:10.1073/pnas.1016140108
   PubMed Web of Science ®Google Scholar
• Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69(24):9330–9336. doi:10.1158/0008-5472.CAN-08-4597
   PubMed Web of Science ®Google Scholar
• Mamidi S, Cinci M, Hasmann M, Fehring V, Kirschfink M. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab. Mol Oncol. 2013;7(3):580–594. doi:10.1016/j.molonc.2013.02.011
   PubMed Web of Science ®Google Scholar
• Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28(7):1138–1144. doi:10.1200/JCO.2009.24.2024
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–119. doi:10.1056/NEJMoa1113216
   PubMed Web of Science ®Google Scholar
• Swain SM, Kim SB, Cortes J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–471. doi:10.1016/S1470-2045(13)70130-X
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734. doi:10.1056/NEJMoa1413513
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122–131. doi:10.1056/NEJMoa1703643
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800. doi:10.1016/S1470-2045(16)00163-7
   PubMed Web of Science ®Google Scholar
• Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–2284. doi:10.1093/annonc/mdt182
   PubMed Web of Science ®Google Scholar
• Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018;89:27–35. doi:10.1016/j.ejca.2017.10.021
   PubMed Web of Science ®Google Scholar
• Portera CC, Walshe JM, Rosing DR, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res. 2008;14(9):2710–2716. doi:10.1158/1078-0432.CCR-07-4636
   PubMed Web of Science ®Google Scholar
• Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995;378(6555):394–398. doi:10.1038/378394a0
   PubMed Web of Science ®Google Scholar
• Gassmann M, Casagranda F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 1995;378(6555):390–394.
   PubMed Web of Science ®Google Scholar
• Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8(5):459–465. doi:10.1038/nm0502-459
   PubMed Web of Science ®Google Scholar
• Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2002;99(13):8880–8885. doi:10.1073/pnas.122249299
   PubMed Web of Science ®Google Scholar
• Zhao YY, Sawyer DR, Baliga RR, et al. Neuregulins promote survival and growth of cardiac myocytes. persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem. 1998;273(17):10261–10269. doi:10.1074/jbc.273.17.10261
   PubMed Web of Science ®Google Scholar
• Sendur MA, Aksoy S, Altundag K. Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab. Future Oncol. 2015;11(1):13–15. doi:10.2217/fon.14.184
   PubMed Web of Science ®Google Scholar
• Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–1221. doi:10.1200/JCO.2002.20.5.1215
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–1672. doi:10.1056/NEJMoa052306
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–1684. doi:10.1056/NEJMoa052122
   PubMed Web of Science ®Google Scholar
• de Azambuja E, Procter MJ, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin adjuvant trial (BIG 1-01). J Clin Oncol. 2014;32(20):2159–2165. doi:10.1200/JCO.2013.53.9288
   PubMed Web of Science ®Google Scholar
• Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744–3752. doi:10.1200/JCO.2014.55.5730
   PubMed Web of Science ®Google Scholar
• Swain SM, Ewer MS, Viale G, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018;29(3):646–653. doi:10.1093/annonc/mdx773
   PubMed Web of Science ®Google Scholar
• Yu AF, Singh JC, Wang R, et al. Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer. Oncologist. 2017;22(6):642–647. doi:10.1634/theoncologist.2016-0406
   PubMed Web of Science ®Google Scholar
• Bachelot T, Ciruelos E, Schneeweiss A, et al. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol. 2019. doi:10.1016/S0140-6736(13)61094-6
   Google Scholar
• De Lorenzo C, Paciello R, Riccio G, et al. Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine. Onco Targets Ther. 2018;11:2241–2250. doi:10.2147/OTT.S157294
   PubMed Web of Science ®Google Scholar
• Perjeta® (pertuzumab) injection, for intravenous use [package insert]. San Francisco, CA: Genentech, Inc; 2018.
   Google Scholar
• Zhu C, Ling W, Zhang J, Gao H, Shen K, Ma X. Safety and efficacy evaluation of pertuzumab in patients with solid tumors. Medicine (Baltimore). 2017;96(20):e6870. doi:10.1097/MD.0000000000006870
   PubMed Web of Science ®Google Scholar
• Van Sebille YZ, Gibson RJ, Wardill HR, Bowen JM. ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: chloride secretion as a mechanistic hypothesis. Cancer Treat Rev. 2015;41(7):646–652. doi:10.1016/j.ctrv.2015.05.011
   PubMed Web of Science ®Google Scholar
• Melosky B. Supportive care treatments for toxicities of anti-EGFR and other targeted agents. Curr Oncol. 2012;19(Suppl 1):S59–S63. doi:10.3747/co.19.1054
   PubMedGoogle Scholar
• Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer. 2006;14(9):890–900. doi:10.1007/s00520-006-0040-y
   PubMed Web of Science ®Google Scholar
• Swain SM, Schneeweiss A, Gianni L, et al. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Ann Oncol. 2017;28(4):761–768. doi:10.1093/annonc/mdw695
   PubMed Web of Science ®Google Scholar
• Hussain N, Said ASA, Khan Z. Safety assessment of neoadjuvant pertuzumab combined with trastuzumab in nonmetastatic HER2-positive breast cancer in postmenopausal elderly women of South Asia. Int J Breast Cancer. 2018;2018:6106041. doi:10.1155/2018/6106041
   PubMed Web of Science ®Google Scholar
• Wu PE, Juurlink DN. Clinical review: loperamide toxicity. Ann Emerg Med. 2017;70(2):245–252. doi:10.1016/j.annemergmed.2017.04.008
   PubMed Web of Science ®Google Scholar
• Gao JJ, Tan M, Pohlmann PR, Swain SM. HALT-D: a phase II evaluation of crofelemer for the prevention and prophylaxis of diarrhea in patients with breast cancer on pertuzumab-based regimens. Clin Breast Cancer. 2017;17(1):76–78. doi:10.1016/j.clbc.2016.08.005
   PubMed Web of Science ®Google Scholar
• Squires H, Pandor A, Thokala P, et al. Pertuzumab for the neoadjuvant treatment of early-stage HER2-positive breast cancer: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018;36(1):29–38. doi:10.1007/s40273-017-0556-7
   PubMed Web of Science ®Google Scholar
• van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1630–1640. doi:10.1016/S1470-2045(18)30570-9
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19(1):115–126. doi:10.1016/S1470-2045(17)30716-7
   PubMed Web of Science ®Google Scholar
• Bulbul A, Araujo-Mino E, Dayao ZR. The conundrum of adjuvant HER2 treatment options. Front Oncol. 2018;8:177. doi:10.3389/fonc.2018.00177
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382(9897):1021–1028. doi:10.1016/S0140-6736(13)61094-6
   PubMed Web of Science ®Google Scholar
• Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367–377. doi:10.1016/S1470-2045(15)00551-3
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372(2):134–141. doi:10.1056/NEJMoa1406281
   PubMed Web of Science ®Google Scholar
• Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol. 2011;29(16):2144–2149. doi:10.1200/JCO.2010.31.5374
   PubMed Web of Science ®Google Scholar
• Miles D, Im YH, Fung A, et al. Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial. Ann Oncol. 2017;28(11):2761–2767. doi:10.1093/annonc/mdx406
   PubMed Web of Science ®Google Scholar
• Dang C, Iyengar N, Datko F, et al. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015;33(5):442–447. doi:10.1200/JCO.2014.57.1745
   PubMed Web of Science ®Google Scholar
• Smyth LM, Iyengar NM, Chen MF, et al. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast Cancer Res Treat. 2016;158(1):91–97. doi:10.1007/s10549-016-3851-7
   PubMed Web of Science ®Google Scholar
• Inoue K, Ninomiya J, Saito T, et al. Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial. Invest New Drugs. 2019;37(3):538–547. doi:10.1007/s10637-019-00755-x
   PubMed Web of Science ®Google Scholar
• Andersson M, Lopez-Vega JM, Petit T, et al. Efficacy and safety of pertuzumab and trastuzumab administered in a single infusion bag, followed by vinorelbine: VELVET cohort 2 final results. Oncologist. 2017;22(10):1160–1168. doi:10.1634/theoncologist.2017-0079
   PubMed Web of Science ®Google Scholar
• Perez EA, Lopez-Vega JM, Petit T, et al. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET cohort 1 final results. Breast Cancer Res. 2016;18(1):126-016-0773-6. doi:10.1186/s13058-016-0773-6
   PubMedGoogle Scholar
• Urruticoechea A, Rizwanullah M, Im SA, et al. Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy. J Clin Oncol. 2017;35(26):3030–3038. doi:10.1200/JCO.2016.70.6267
   PubMed Web of Science ®Google Scholar
• Untch M, Jackisch C, Schneeweiss A, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): A randomised, phase 3 trial. Lancet Oncol. 2016;17(3):345–356. doi:10.1016/S1470-2045(15)00542-2
   PubMed Web of Science ®Google Scholar
• Sawaki M, Tokudome N, Mizuno T, et al. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07). Jpn J Clin Oncol. 2011;41(5):709–712. doi:10.1093/jjco/hyr011
   PubMed Web of Science ®Google Scholar
• Okines AF. T-DM1 in the neo-adjuvant treatment of HER2-positive breast cancer: impact of the KRISTINE (TRIO-021) trial. Rev Recent Clin Trials. 2017;12(3):216–222. doi:10.2174/1574887112666170529094911
   PubMedGoogle Scholar
• Amler LC. HER3 mRNA as a predictive biomarker in anticancer therapy. Expert Opin Biol Ther. 2010;10(9):1343–1355. doi:10.1517/14712598.2010.512003
   PubMed Web of Science ®Google Scholar
• Thomas G, Chardes T, Gaborit N, et al. HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget. 2014;5(16):7138–7148. doi:10.18632/oncotarget.2231
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortes J, Im SA, et al. Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014;32(33):3753–3761. doi:10.1200/JCO.2013.54.5384
   PubMed Web of Science ®Google Scholar
• Schneeweiss A, Chia S, Hegg R, et al. Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study. Breast Cancer Res. 2014;16(4):R73. doi:10.1186/s13058-014-0492-9
   PubMed Web of Science ®Google Scholar
• Cizkova M, Susini A, Vacher S, et al. PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups. Breast Cancer Res. 2012;14(1):R28. doi:10.1186/bcr3169
   PubMed Web of Science ®Google Scholar
• Luen SJ, Salgado R, Fox S, et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 2017;18(1):52–62. doi:10.1016/S1470-2045(16)30631-3
   PubMed Web of Science ®Google Scholar
• Luo C, Chen S, Xu N, et al. Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties. Sci Rep. 2017;7:46347. doi:10.1038/srep46347
   PubMed Web of Science ®Google Scholar
• Attard CL, Pepper AN, Brown ST, et al. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. J Med Econ. 2015;18(3):173–188. doi:10.3111/13696998.2014.979938
   PubMed Web of Science ®Google Scholar
• Durkee BY, Qian Y, Pollom EL, et al. Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2016;34(9):902–909. doi:10.1200/JCO.2015.62.9105
   PubMed Web of Science ®Google Scholar
• Diaby V, Ali AA, Williams KJ, et al. Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. Breast Cancer Res Treat. 2017;166(3):951–963. doi:10.1007/s10549-017-4473-4
   PubMed Web of Science ®Google Scholar
• Garrison LP Jr, Babigumira J, Tournier C, Goertz HP, Lubinga SJ, Perez EA. Cost-effectiveness analysis of pertuzumab with trastuzumab and chemotherapy compared to trastuzumab and chemotherapy in the adjuvant treatment of HER2-positive breast cancer in the united states. Value Health. 2019;22(4):408–415. doi:10.1016/j.jval.2018.11.014
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018;36(6):536–542. doi:10.1200/JCO.2017.75.3780
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697. doi:10.1016/S0140-6736(10)61121-X
   PubMed Web of Science ®Google Scholar
• Tabernero J, Hoff PM, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19(10):1372–1384. doi:10.1016/S1470-2045(18)30481-9
   PubMed Web of Science ®Google Scholar
• Kurzeder C, Bover I, Marme F, et al. Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-expressing platinum-resistant ovarian cancer (PENELOPE). J Clin Oncol. 2016;34(21):2516–2525. doi:10.1200/JCO.2015.66.0787
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121. doi:10.1056/NEJMoa1809615
   PubMed Web of Science ®Google Scholar
• Connolly RM, Leal JP, Solnes L, et al. TBCRC026: phase II trial correlating standardized uptake value with pathologic complete response to pertuzumab and trastuzumab in breast cancer. J Clin Oncol. 2019;37(9):714–722. doi:10.1200/JCO.2018.78.7986
   PubMed Web of Science ®Google Scholar